{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:35:58Z","timestamp":1794472558109,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Metabolic reprogramming is a hallmark of cancer, with acute myeloid leukemia (AML) being no exception. Mitochondrial function, particularly its role in protecting tumor cells against chemotherapy, is of significant interest in AML chemoresistance. In this study, we identified mitochondrial DNA content (mtDNAc), measured by quantitative PCR, as a simple and precise marker to stratify the metabolic states of AML patients. We show that patients with high mtDNAc are associated with increased mitochondrial metabolism and a higher dependency on oxidative phosphorylation (OXPHOS), often correlating with chemoresistance. Clinically, patients receiving cytarabine and an anthracycline-based regimen (7\u2009+\u20093 regimen) experienced inferior relapse-free survival and a higher overall rate of leukemia recurrence. Ex vivo experiments using primary AML samples confirmed cytarabine resistance in high mtDNAc patients, which could be overcome by inhibiting mitochondrial complex I. The FDA-approved drug metformin, which targets mitochondrial metabolism, significantly enhanced apoptosis in response to chemotherapy or targeted agents, such as venetoclax, in AML models. However, metformin-treated cells adapted by increasing glycolysis and NAD<jats:sup>+<\/jats:sup> production, a resistance mechanism that could be bypassed by targeting the nicotinamide phosphoribosyltransferase (NAMPT) enzyme. In summary, we demonstrated that mtDNAc is an effective tool for assessing the metabolic state of AML cells. This method can be easily implemented in clinical practice to identify chemoresistant patients and guide personalized treatment strategies, including novel combination therapies for those with a high reliance on mitochondrial metabolism.<\/jats:p>","DOI":"10.1038\/s41392-025-02303-x","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T23:02:18Z","timestamp":1752447738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-4311","authenticated-orcid":false,"given":"Diego A.","family":"Pereira-Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Weinh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Griessinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Coelho-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Sternadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Kosa L.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-4100","authenticated-orcid":false,"given":"Prodromos","family":"Chatzikyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Bruno","family":"Alves-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-289X","authenticated-orcid":false,"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Olalla Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobien R.","family":"Hilberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Moreira-Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Salustiano-Bandeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus M.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Franca-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos A.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha K.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ammatuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-4086","authenticated-orcid":false,"given":"Eduardo M.","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio R.","family":"Lucena-Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2303_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"2303_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2303_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol, F. & Ganser, A. Treatment of relapsed acute myeloid leukemia. Curr. Treat. Options Oncol. 21, 66 (2020).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2303_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli, I. et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell 36, 84\u201399.e8 (2019).","journal-title":"Cancer Cell"},{"key":"2303_CR5","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2352-3026(23)00159-X","volume":"10","author":"RM Shallis","year":"2023","unstructured":"Shallis, R. M. et al. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 10, e767\u2013e776 (2023).","journal-title":"Lancet Haematol."},{"key":"2303_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi, Y. et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat. Commun. 13, 4622 (2022).","journal-title":"Nat. Commun."},{"key":"2303_CR7","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"C Bosc","year":"2021","unstructured":"Bosc, C. et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat. Cancer 2, 1204\u20131223 (2021).","journal-title":"Nat. Cancer"},{"key":"2303_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser, S. & Levis, M. J. Updates on targeted therapies for acute myeloid leukaemia. Br. J. Haematol. 196, 316\u2013328 (2022).","journal-title":"Br. J. Haematol."},{"key":"2303_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850\u2013864.e9 (2022).","journal-title":"Cancer Cell"},{"key":"2303_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29, 115\u2013126 (2023).","journal-title":"Nat. Med."},{"key":"2303_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23\u201337 (2016).","journal-title":"Cell Stem Cell"},{"key":"2303_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30223-9","volume":"13","author":"MA Bassal","year":"2022","unstructured":"Bassal, M. A. et al. Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nat. Commun. 13, 2614 (2022).","journal-title":"Nat. Commun."},{"key":"2303_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29639-0","volume":"13","author":"A Erdem","year":"2022","unstructured":"Erdem, A. et al. Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability. Nat. Commun. 13, 2013 (2022).","journal-title":"Nat. Commun."},{"key":"2303_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fphys.2013.00207","volume":"4","author":"S Javadov","year":"2013","unstructured":"Javadov, S. & Kuznetsov, A. V. Mitochondria: the cell powerhouse and nexus of stress. Front. Physiol. 4, 207 (2013).","journal-title":"Front. Physiol."},{"key":"2303_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2023.100113","volume":"2","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Mitochondrial DNA-targeted therapy: a novel approach to combat cancer. Cell Insight 2, 100113 (2023).","journal-title":"Cell Insight"},{"key":"2303_CR16","doi-asserted-by":"publisher","first-page":"22834","DOI":"10.18632\/oncotarget.8071","volume":"7","author":"X He","year":"2016","unstructured":"He, X. et al. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget 7, 22834\u201322845 (2016).","journal-title":"Oncotarget"},{"key":"2303_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/carcin\/bgv042","volume":"36","author":"F Qu","year":"2015","unstructured":"Qu, F. et al. Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Carcinogenesis 36, 543\u2013552 (2015).","journal-title":"Carcinogenesis"},{"key":"2303_CR18","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.5301\/jbm.5000211","volume":"31","author":"Y Wang","year":"2016","unstructured":"Wang, Y., He, S., Zhu, X., Qiao, W. & Zhang, J. High copy number of mitochondrial DNA predicts poor prognosis in patients with advanced stage colon cancer. Int. J. Biol. Markers 31, e382\u2013e388 (2016).","journal-title":"Int. J. Biol. Markers"},{"key":"2303_CR19","doi-asserted-by":"publisher","first-page":"29166","DOI":"10.18632\/oncotarget.8688","volume":"7","author":"MJA Weerts","year":"2016","unstructured":"Weerts, M. J. A. et al. Mitochondrial DNA content in breast cancer: impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget 7, 29166\u201329176 (2016).","journal-title":"Oncotarget"},{"key":"2303_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1746-1596-9-28","volume":"9","author":"S Dang","year":"2014","unstructured":"Dang, S. et al. Low copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in early-stage laryngeal cancer patients. Diagn. Pathol. 9, 28 (2014).","journal-title":"Diagn. Pathol."},{"key":"2303_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.mito.2021.03.013","volume":"58","author":"S Chaudhary","year":"2021","unstructured":"Chaudhary, S. et al. PGC1A driven enhanced mitochondrial DNA copy number predicts outcome in pediatric acute myeloid leukemia. Mitochondrion 58, 246\u2013254 (2021).","journal-title":"Mitochondrion"},{"key":"2303_CR22","doi-asserted-by":"publisher","first-page":"1109518","DOI":"10.3389\/fonc.2023.1109518","volume":"13","author":"S Chaudhary","year":"2023","unstructured":"Chaudhary, S. et al. Mitochondrial gene expression signature predicts prognosis of pediatric acute myeloid leukemia patients. Front. Oncol. 13, 1109518 (2023).","journal-title":"Front. Oncol."},{"key":"2303_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41375-022-01796-7","volume":"37","author":"S Stratmann","year":"2023","unstructured":"Stratmann, S. et al. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia 37, 550\u2013559 (2023).","journal-title":"Leukemia"},{"key":"2303_CR24","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2008-05-157974","volume":"112","author":"Q Lan","year":"2008","unstructured":"Lan, Q. et al. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. Blood 112, 4247\u20134249 (2008).","journal-title":"Blood"},{"key":"2303_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjh.18510","volume":"200","author":"DA Pereira-Martins","year":"2023","unstructured":"Pereira-Martins, D. A. et al. Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia. Br. J. Haem. 200, 170\u2013174 (2023).","journal-title":"Br. J. Haem."},{"key":"2303_CR26","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei, Y. et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front. Oncol. 10, 584974 (2020).","journal-title":"Front. Oncol."},{"key":"2303_CR27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva, M. & Letai, A. BCL-2 inhibition in AML: an unexpected bonus?. Blood 132, 1007\u20131012 (2018).","journal-title":"Blood"},{"key":"2303_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28737-3","volume":"13","author":"A Erdem","year":"2022","unstructured":"Erdem, A. et al. The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia. Nat. Commun. 13, 1105 (2022).","journal-title":"Nat. Commun."},{"key":"2303_CR29","doi-asserted-by":"publisher","first-page":"eadf8522","DOI":"10.1126\/sciadv.adf8522","volume":"9","author":"I Weinh\u00e4user","year":"2023","unstructured":"Weinh\u00e4user, I. et al. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism. Sci. Adv. 9, eadf8522 (2023).","journal-title":"Sci. Adv."},{"key":"2303_CR30","unstructured":"Stuani, L. et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J. Exp. Med. 218, e20200924 (2021)."},{"key":"2303_CR31","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212\u20131223 (2022).","journal-title":"Nat. Med."},{"key":"2303_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"2303_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","volume":"25","author":"H Li","year":"2019","unstructured":"Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. 25, 850\u2013860 (2019).","journal-title":"Nat. Med."},{"key":"2303_CR34","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/bloodadvances.2019001419","volume":"4","author":"DRA Silveira","year":"2020","unstructured":"Silveira, D. R. A. et al. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 4, 2339\u20132350 (2020).","journal-title":"Blood Adv."},{"key":"2303_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3324\/haematol.2018.195172","volume":"104","author":"D Yehudai","year":"2019","unstructured":"Yehudai, D. et al. The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase \u03b3, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. Haematologica 104, 963\u2013972 (2019).","journal-title":"Haematologica"},{"key":"2303_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41467-017-02465-5","volume":"9","author":"S-I Lee","year":"2018","unstructured":"Lee, S.-I. et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat. Comm. 9, 42 (2018).","journal-title":"Nat. Comm."},{"key":"2303_CR37","doi-asserted-by":"crossref","unstructured":"Dong, L., Gopalan, V., Holland, O. & Neuzil, J. Mitocans revisited: mitochondrial targeting as efficient anti-cancer therapy. Int. J. Mol. Sci. 21, 7941 (2020).","DOI":"10.3390\/ijms21217941"},{"key":"2303_CR38","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716\u2013735 (2017).","journal-title":"Cancer Discov."},{"key":"2303_CR39","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/leu.2013.107","volume":"27","author":"S Scotland","year":"2013","unstructured":"Scotland, S. et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 27, 2129\u20132138 (2013).","journal-title":"Leukemia"},{"key":"2303_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).","journal-title":"eLife"},{"key":"2303_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Eng. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Eng. J. Med."},{"key":"2303_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"2303_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826\u2013839 (2020).","journal-title":"Nat. Cancer"},{"key":"2303_CR44","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 13, 2032\u20132049 (2023).","journal-title":"Cancer Discov."},{"key":"2303_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"2303_CR46","doi-asserted-by":"crossref","unstructured":"Culp-Hill, R. et al. Therapy-resistant acute myeloid leukemia stem cells are resensitized to venetoclax + azacitidine by targeting fatty acid desaturases 1 and 2. Metabolites 13, 467 (2023).","DOI":"10.3390\/metabo13040467"},{"key":"2303_CR47","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens, B. M. et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Cancer 1, 1176\u20131187 (2020).","journal-title":"Nat. Cancer"},{"key":"2303_CR48","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones, C. L. et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell 27, 748\u2013764.e4 (2020).","journal-title":"Cell Stem Cell"},{"key":"2303_CR49","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.stem.2021.06.004","volume":"28","author":"A Subedi","year":"2021","unstructured":"Subedi, A. et al. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell 28, 1851\u20131867.e8 (2021).","journal-title":"Cell Stem Cell"},{"key":"2303_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41588-019-0557-x","volume":"52","author":"Y Yuan","year":"2020","unstructured":"Yuan, Y. et al. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat. Genet. 52, 342\u2013352 (2020).","journal-title":"Nat. Genet."},{"key":"2303_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze, R. et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell 36, 369\u2013384.e13 (2019).","journal-title":"Cancer Cell"},{"key":"2303_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15051-z","volume":"11","author":"R Bajpai","year":"2020","unstructured":"Bajpai, R. et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat. Commun. 11, 1228 (2020).","journal-title":"Nat. Commun."},{"key":"2303_CR53","doi-asserted-by":"crossref","unstructured":"Sharon, D. et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci. Transl. Med. 11, eaax2863 (2019).","DOI":"10.1126\/scitranslmed.aax2863"},{"key":"2303_CR54","doi-asserted-by":"crossref","unstructured":"Park, H. J. et al. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation. eLife 11, e79940 (2022).","DOI":"10.7554\/eLife.79940"},{"key":"2303_CR55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SWK Ng","year":"2016","unstructured":"Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"2303_CR56","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1182\/blood-2010-08-303479","volume":"117","author":"F Damm","year":"2011","unstructured":"Damm, F. et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117, 4561\u20134568 (2011).","journal-title":"Blood"},{"key":"2303_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","volume":"128","author":"R Moschoi","year":"2016","unstructured":"Moschoi, R. et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood 128, 253\u2013264 (2016).","journal-title":"Blood"},{"key":"2303_CR58","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5966\/sctm.2013-0166","volume":"3","author":"E Griessinger","year":"2014","unstructured":"Griessinger, E. et al. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl. Med. 3, 520\u2013529 (2014).","journal-title":"Stem Cells Transl. Med."},{"key":"2303_CR59","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2018.08.014","volume":"34","author":"B de Boer","year":"2018","unstructured":"de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34, 674\u2013689.e8 (2018).","journal-title":"Cancer Cell"},{"key":"2303_CR60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264\u2013278 (2012).","journal-title":"Cell"},{"key":"2303_CR61","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas, D. & Majeti, R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129, 1577\u20131585 (2017).","journal-title":"Blood"},{"key":"2303_CR62","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones, C. L. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 34, 724\u2013740.e4 (2018).","journal-title":"Cancer Cell"},{"key":"2303_CR63","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1182\/blood-2018-99-112210","volume":"132","author":"S Roy Chowdhury","year":"2018","unstructured":"Roy Chowdhury, S. et al. Venetoclax in combination with NAMPT inhibitors decreases mitochondrial bioenergetics through the impaired AMPK\/SIRT\/PGC1\u03b1 signaling pathway in CLL. Blood 132, 1368\u20131368 (2018).","journal-title":"Blood"},{"key":"2303_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2159-8290.CD-21-0218","volume":"13","author":"D Thomas","year":"2023","unstructured":"Thomas, D. et al. Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Disc 13, 496\u2013515 (2023).","journal-title":"Cancer Disc"},{"key":"2303_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178\u2013184 (2015).","journal-title":"Nat. Med."},{"key":"2303_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2643-3230.BCD-23-0195","volume":"5","author":"N Landberg","year":"2023","unstructured":"Landberg, N. et al. IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation. Blood Cancer Discov. 5, 114\u2013131 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2303_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2643-3230.BCD-23-0255","volume":"5","author":"DP Steensma","year":"2024","unstructured":"Steensma, D. P. Altered oxidative phosphorylation confers vulnerability on IDH1-mutant leukemia cells: is this therapeutically tractable? Blood Cancer Discov. 5, 83\u201385 (2024).","journal-title":"Blood Cancer Discov."},{"key":"2303_CR68","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1182\/blood-2024-210847","volume":"144","author":"MP de Lacerda","year":"2024","unstructured":"de Lacerda, M. P. et al. Safety and efficacy of venetoclax, cytarabine and metformin for relapsed-refractory and induction-ineligible acute myeloid leukemia. Blood 144, 1524\u20131524 (2024).","journal-title":"Blood"},{"key":"2303_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91174-7","volume":"11","author":"E Sutkowska","year":"2021","unstructured":"Sutkowska, E. et al. Low metformin dose and its therapeutic serum concentration in prediabetes. Sci. Rep. 11, 11684 (2021).","journal-title":"Sci. Rep."},{"key":"2303_CR70","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/s41375-022-01635-9","volume":"36","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia. Leukemia 36, 2196\u20132207 (2022).","journal-title":"Leukemia"},{"key":"2303_CR71","doi-asserted-by":"crossref","unstructured":"Liu, L. et al. High Metabolic dependence on oxidative phosphorylation drives sensitivity to metformin treatment in MLL\/AF9 acute myeloid leukemia. Cancers 14, 486 (2022).","DOI":"10.3390\/cancers14030486"},{"key":"2303_CR72","doi-asserted-by":"crossref","unstructured":"Parisotto, M. et al. The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells. Cancers 14, 5597 (2022).","DOI":"10.3390\/cancers14225597"},{"key":"2303_CR73","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/toxsci\/kfu268","volume":"144","author":"TS Zabka","year":"2015","unstructured":"Zabka, T. S. et al. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol. Sci. 144, 163\u2013172 (2015).","journal-title":"Toxicol. Sci."},{"key":"2303_CR74","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1101\/gr.250480.119","volume":"29","author":"R O\u2019Hara","year":"2019","unstructured":"O\u2019Hara, R. et al. Quantitative mitochondrial DNA copy number determination using droplet digital PCR with single-cell resolution. Genome Res. 29, 1878\u20131888 (2019).","journal-title":"Genome Res."},{"key":"2303_CR75","volume":"9","author":"A Gu","year":"2013","unstructured":"Gu, A. et al. Alterations in mitochondrial DNA copy number and the activities of electron transport chain complexes and pyruvate dehydrogenase in the frontal cortex from subjects with autism. Transl. Psychiatry 9, 1038 (2013).","journal-title":"Transl. Psychiatry"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02303-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02303-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02303-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:27:42Z","timestamp":1757219262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02303-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02303-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}